Avadel Pharmaceuticals (AVDL) Invested Capital (2016 - 2022)
Historic Invested Capital for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $123.8 million.
- Avadel Pharmaceuticals' Invested Capital fell 4864.28% to $123.8 million in Q3 2022 from the same period last year, while for Dec 2022 it was $726000.0, marking a year-over-year decrease of 9967.1%. This contributed to the annual value of $220.6 million for FY2021, which is 2404.16% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Invested Capital of $123.8 million as of Q3 2022, which was down 4864.28% from $131.0 million recorded in Q2 2022.
- Avadel Pharmaceuticals' 5-year Invested Capital high stood at $307.0 million for Q2 2020, and its period low was $89.7 million during Q2 2018.
- Its 5-year average for Invested Capital is $183.4 million, with a median of $180.2 million in 2018.
- Per our database at Business Quant, Avadel Pharmaceuticals' Invested Capital surged by 228243.23% in 2018 and then crashed by 4974.83% in 2022.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Invested Capital stood at $118.6 million in 2018, then decreased by 22.03% to $92.5 million in 2019, then skyrocketed by 214.07% to $290.5 million in 2020, then fell by 24.04% to $220.6 million in 2021, then crashed by 43.89% to $123.8 million in 2022.
- Its last three reported values are $123.8 million in Q3 2022, $131.0 million for Q2 2022, and $197.9 million during Q1 2022.